HIV-1 Diversity in the Envelope Glycoproteins: Implications for Viral Entry Inhibition

Leonardo Augusto Luvison Araújo * and Sabrina E. M. Almeida

Centro de Desenvolvimento Científico e Tecnológico (CDCT), Fundação Estadual de Produção e Pesquisa em Saúde (FEPPS), Porto Alegre, 90610-000, Brazil

* Author to whom correspondence should be addressed; E-Mail: leonardo_luvison@hotmail.com; Tel.: +55-51-3339-2386; Fax: +55-51-3339-3654.

Received: 12 December 2012; in revised form: 24 January 2013 / Accepted: 31 January 2013 / Published: 6 February 2013

Abstract: Entry of HIV-1 into a host cell is a multi-step process, with the viral envelope gp120 and gp41 acting sequentially to mediate the viral attachment, CD4 binding, coreceptor binding, and fusion of the viral and host membranes. The emerging class of antiretroviral agents, collectively known as entry inhibitors, interfere in some of these steps. However, viral diversity has implications for possible differential responses to entry inhibitors, since envelope is the most variable of all HIV genes. Different HIV genetic forms carry in their genomes genetic signatures and polymorphisms that could alter the structure of viral proteins which are targeted by drugs, thus impairing antiretroviral binding and efficacy. This review will examine current research that describes subtype differences in envelope at the genetic level and the effects of mutations on the efficacy of current entry inhibitors.

Keywords: HIV-1; entry inhibitors; envelope; diversity

1. Introduction

Human immunodeficiency virus (HIV) is the etiologic agent of acquired immuno-deficiency syndrome (AIDS), one of the most devastating infectious diseases to have emerged in recent history. The origin of pandemic form of HIV-1, the main (M) group, has been traced to a simian immunodeficiency virus (SIV), which was probably passed from chimpanzees to human hunters through bloodborne transmission [1]. HIV-1 evolves quickly due a rapid reproductive rate and reverse
transcriptase is error prone. Thus several intrinsic mechanisms as well as dissemination involved a number of population bottlenecks ensure rapid viral evolution leading to the predominance of different group M lineages around the world. HIV-1 group M has been currently divided into lineages or subtypes A, B, C, D, F, G, H, J, and K as well as circulating recombinant forms (CRFs) and unique recombinant forms (URFs) [1,2]. Genetic variation within a subtype can be 15 to 20%, whereas variation between subtypes is usually 25% to 35%. Differential characteristics of viral subtypes and their interactions with the human host may influence HIV transmission and antiretroviral therapy. The most striking changes in diversity are in the envelope glycoproteins (Env) gp41 and gp120, which are associated with viral transmission [3] and host cell tropism [4]. The gp41 plays a crucial role in the depletion of CD4+ T cells by inducing the death of cell. HIV-1 envelope glycoprotein-mediated entry and fusion have been a target for the development of antiretrovirals, known as entry inhibitors [5]. This review will examine current research that describes subtype differences in envelope at the genetic level and the effects of resistance mutations on the efficacy of current entry inhibitors.

2. HIV Entry and Its Inhibition

Significant progress has been made in understanding HIV-1 envelope structure and the process of entry into a host cell. The envelope gene encodes a protein precursor gp160, which undergoes maturation steps in the endoplasmic reticulum yielding the surface unit gp120 and the transmembrane region gp41 [6]. For entry of HIV-1 into a target cell, the gp120 subunit of the viral envelope glycoprotein associates with the CD4 receptor and the CCR5 coreceptor, inducing a series of conformational changes in Env that culminate in virus and host cell membrane fusion. Most primary HIV-1 strains use the chemokine receptor CCR5 as coreceptor in conjunction with CD4 for virus entry; however, some strains evolve to use a related receptor, CXCR4, either in place or in addition to CCR5 [7]. The coreceptor binding triggers the gp41 N-terminal heptad region (HR1 or NHR) and the C-terminal heptad region (HR2 or CHR) exposure, forming a triple-stranded coiled-coil that approaches the host and viral membranes, forcing the fusion peptides into the target cell membrane. The gp120-gp41 complex undergoes a series of conformational changes during the entry process. Knowledge of these steps in order to design entry inhibitors is very important, since rational drug discovery is based on an understanding at the molecular level of the process to be inhibited [8]. Nevertheless, many details are missing and many challenges remain in achieving this goal. There are several possible targets for the development of drugs with synergistic effects in inhibiting viral entry steps at which interference with the process can be attempted. Generally, these targets can affect viral entry by inhibition of CD4 binding, inhibition of coreceptor binding (CCR5 antagonists), and blocking of the gp41 conformational changes that permit viral fusion (Fusion inhibitors) (Figure 1). For more details, see the review [9]. To the best of our knowledge, only two entry inhibitors have been approved by the Food and Drug Administration (FDA): enfuvirtide (T20), a fusion inhibitor, and selzentry (maraviroc), a CCR5 antagonist. One additional entry inhibitor in an advanced stage of clinical development is the CCR5 antagonist vicriviroc (SCH 417690); however, due to results obtained in a recent phase III trial development will be discontinued.
Figure 1. Ribbon diagram of gp120 (pdb 2QAD), bovine rhodopsin (pdb 1F88A) and SIV gp41 (pdb 1QBZ). (a) Ribbon diagram of gp120 (shown in green) bound to CD4 and Fab 17b (not show). The sites related to vicriviroc (305, 308, 315), maraviroc (316, 323) and BMS-806 (426, 434, 475) resistance is shown (in red, blue and magenta, respectively). (b) Structure of bovine rhodopsin, used as template in homology modeling procedure to CCR5. All CCR5 inhibitors are believed to occupy a binding pocket formed at the base of the extra cellular loops of the CCR5 receptor (shown in blue). (c) gp41 enfuvirtide bind site and resistance mutations (36, 37, 38, 40, 42, 43, 89). Residues in light blue correspond to both the enfuvirtide binding site and the resistance mutations.

3. Diversity in the Envelope Glycoproteins

As stated earlier, group M is responsible for the current AIDS pandemic and exhibits exceedingly high levels of viral genetic diversity. The subtypes of group M can differ by around 35% in the envelope glycoproteins of the virus (Figure 2). The pattern of diversity and adaptive evolution in the
Env gene was examined by several studies, as in Choisy et al. and Travers et al., that used multiple subtypes to identify sites evolving under positive selection in gp120 and gp41 [10,11]. A large number of amino acid sites are evolving under positive selection in HIV-1 group M envelope protein. When the selection pressure is compared by subtype, several sites are under positive pressure in some subtypes and under negative pressure in others. The presence of such sites indicates unique selective pressures for particular subtypes, which may lead to different phenotypic characteristics within HIV-1 group M evolution and account for the various levels of fitness. Insertion and deletion events occur throughout Env and are maintained through positive selection, particularly within the hypervariable loops, which acquire significant length variation [12,13].

Figure 2. Schematic view of the HIV-1 HXB2 gp120 and gp41 molecules. Boxes designate crucial regions involved in resistance to entry inhibitors. The sequences contain representative alignment of each HIV-1 group M subtype (obtained in Los Alamos HIV database). (a) The constant (C1, C2, C3, C4, C5) and variable regions (V1, V2, V3, V4, V5) of gp120. Changes in gp120 C2, V3 and C4 are related to resistance to the CCR5 antagonist and CD4-gp120 inhibitor. The arrow points to the end of the V3 loop where the resistance mutations to CCR5 agonists are located (b) Schematic diagram of HIV-1 gp41. FP, fusion peptide; NHR, N-terminal heptad repeat; CHR, C-terminal heptad repeat; MPER, membrane-proximal external region; TM, transmembrane domain of gp41; CP, cytoplasmic domain. The fusion inhibitor enfuvirtide targets the GIV motif in the NHR. The mutations leading to resistance to enfuvirtide are located between residues 36-45 in the NHR region of gp41 (red band and arrow). Resistance mutations in the CHR region also have been detected.
The tip of the V3 loop, which is a target for antibody neutralization and plays a role in the tropism and infectivity of the virus, seems to be under selection pressure for length as it is almost always 35 residues long [14,15]. Generally, CXCR4-using viruses carry positively charged amino acids at positions 11 and/or 25 in the V3 loop, while CCR5-tropic viruses do not. The tip contains a highly conserved motif, Gly-Pro-Gly-Arg/Gln (GPGR/Q, residues 312–315 in the HXB2 numbering), usually GPGQ among all HIV-1 subtypes, whereas GPGR predominates in the B subtype. The variability and the ratio of non-synonymous ($dN$) to synonymous ($dS$) in a comparison using subtype B and C V3 sequences deposited in the Los Alamos HIV Database exhibits higher entropy and $dN/dS$ ratio in subtype B [16]. Interestingly, the flanking regions of V3 in subtype C exhibits higher entropy and $dN/dS$ ratio than subtype B. These findings suggest that the adaptive pressures that have shaped Env in each lineage are distinct, and this may have formed the basis for conformational differences between subtypes [17,18]. The selective pressure exerted either by CTL or neutralizing antibodies can account for particular evolutionary patterns in the Env gene. Although genetic diversity of the Env has been extensively studied, less information is available concerning functional diversity of these proteins. Studies have focused on subtype-specific conformational differences of the V3 and C3 regions. These studies demonstrate that there are intrinsic differences within the V3 stem and turn region (positions 9 to 24) in entropy and C3 region in entropy and amphipathicity between subtypes B and C [15,19]. Subtype-specific patterns of sequence polymorphism in gp41 HR1 and HR2 regions have also been shown, suggesting that selection pressures could differ between subtypes [20–23]. These studies mainly concentrated on the comparison of subtypes B and C point to possible structural differences, which can give different responses to entry inhibitors. Further studies are needed to...
compare other subtypes to elucidate major structural differences, and to determine how these affect the activity of entry inhibitors.

4. Resistance to Entry Inhibitors

Certain mutations impacting drugs in the entry inhibitor have been identified in vitro passage experiments, examination of clinical isolates and correlation studies between genotype at baseline and virologic response in patients exposed to the drug [24,25]. The most common genetic route to CCR5 inhibitor resistance involves multiple sequence changes in V3 and result in gaining the ability to enter cells using the inhibitor-CCR5 complex while retaining the use of free CCR5 [26]. A rare pathway of HIV-1 resistance to small molecule CCR5 inhibitors such as vicriviroc involves changes solely in the gp41 fusion peptide [27]. These data should be interpreted in light of the fact that subtype B viruses are most frequently used in biological studies of resistance to entry inhibitors. The information on non-B subtypes resistance remains very limited. Araújo et al. and Gonzales et al. showed a high prevalence of resistance mutations for maraviroc and vicriviroc in HIV-1 subtype C, which may suggest a limited efficacy of CCR5 inhibitors in this subtype [28,29]. Natural gp120 variability among different HIV-1 subtypes may account for differences in baseline susceptibility to entry inhibitors. This is the case for subtype C and recombinant subtype AE (CRF01_AE) resistance to CD4–gp120 binding inhibitors, which seem to be naturally resistant to BMS-806 [30].

Studies using enfuvirtide, a fusion inhibitor, showed that differences in the susceptibility of enfuvirtide-naive virus and the development of resistance are associated with changes in a conserved amino acid triad (GIV) at positions 36–38 in the NHR region of gp41 (Figure 2). Mutations in the CHR region also have been detected in enfuvirtide-resistant HIV-1 variants that emerge under the selective pressure of enfuvirtide [31,32]. When analyzing the evolution of Env sequences, enfuvirtide susceptibility, and Env replicative capacity, the epistasis appears to play a critical role in the selection of NHR mutations and the expression of enfuvirtide resistance, altering the evolution of HIV-1 under fusion inhibitor selective pressure [33,34]. The viral envelopes with high-affinity binding to the coreceptor fused more quickly than viral envelopes with lower affinity, reducing the kinetic window during which the viral envelope is sensitive to enfuvirtide [35]. These findings emphasize the complexity involved in the emergence of viral susceptibility to fusion inhibitors, and suggest that the development of resistance can be affected by viral replicative capacity, tropism and coreceptor affinity [36–38]. Since the epistatic effects, tropism and coreceptor affinity differ among subtypes, the resistance may be influenced by the evolutionary history of the HIV strain. For example, there was no evidence for baseline resistance to enfuvirtide in subtype C viruses despite significant differences relative to subtype B in gp41 [39]. In contrast, Yu et al. demonstrates that there were significant differences in baseline susceptibility to HIV entry inhibitors among B’ isolates (also known as Thai B), CRF07_BC and CRF01_AE [40]. Since the majority of HIV-1 infections worldwide involve non-subtype B subtypes and genetic diversity is increasing, additional studies of baseline resistance to entry inhibitors against non-subtype B viruses will be important from a global perspective.

In summary, differences in amino acid composition between HIV-1 clades can lead to differences in susceptibility to ARV drugs. Susceptibility of non-B subtypes to ARV drugs has been less well studied than subtype B mainly because of the predominance of subtype B in developed countries. Therefore, the extreme genetic diversity in envelope of HIV-1 poses a significant challenge for entry inhibitors
design and rational of optimal therapeutic regimens to treat patients. Studies that continue to uncover subtype-specific differences in Env function and structure will be necessary both for discovering new inhibitors and to improving the therapeutic applications for entry inhibitors.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Taylor, B.S.; Sobieszczyk, M.E.; McCutchan, F.E.; Hammer, S.M. The challenge of HIV-1 subtype diversity. *N Engl. J. Med.* 2008, 358, 1590–1602.
2. Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS Pandemic. *Cold Spring Harbor Laboratory Press* 2011, 1, 1.
3. Herbeck, J.T.; Nickle, D.C.; Learn, G.H.; Gottlieb, G.S.; Curlin, M.E.; Heath, L.; Mullins, J.I. Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. *J. Virol.* 2006, 80, 1637–1644.
4. Yang, Z.; Chakrabarti, B.K.; Xu, L.; Welcher, B.; Kong, W.; Leung, K.; Panet, A.; Mascola, J.R.; Nabel, G.J. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. *J. Virol.* 2004, 78, 4029–4036.
5. Wainberg, M.A.; Brenner, B.G. Role of HIV subtype diversity in the development of resistance to antiviral drugs. *Viruses* 2010, 2, 2493–2508.
6. Wilen, C.B.; Tilton, J.C.; Doms, R.W. Molecular mechanisms of HIV entry. *Viral Molecular Machines* 2012, 726, 223–242.
7. Sundaravaradan, V.; Das, S.R.; Ramakrishnan, R.; Sehgal, S.; Gopalan, S.; Ahmad, N.; Jameel, S. Role of HIV-1 subtype C envelope V3 to V5 regions in viral entry, coreceptor utilization and replication efficiency in primary T-lymphocytes and monocyte-derived macrophages. *Virol. J.* 2007, 4, 126.
8. Caffrey, M. HIV envelope: Challenges and opportunities for development of entry inhibitors. *Trends Microbiol.* 2011, 19, 191–197.
9. Lobritz, M.A.; Ratcliff, A.N.; Arts, E.J. HIV-1 entry, inhibitors, and resistance. *Viruses* 2010, 2, 1069–1105.
10. Choisy, M.; Woelk, C.H.; Guégan, J.F.; Robertson, D.L. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. *J. Virol.* 2004, 78, 1962–1970.
11. Travers, S.A.A.; O'Connell, M.J.; McCormack, G.P.; McNerney, J.O. Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes. *J. Virol.* 2005, 79, 1836–1841.
12. Klevytska, A.M.; Mracna, M.R.; Guay, L.; Becker-Pergola, G.; Furtado, M.; Zhang, L.; Jackson, J.B.; Eshleman, S.H. Analysis of length variation in the V1-V2 region of env in nonsubtype B HIV type 1 from Uganda. *AIDS Res. Hum. Retrovir.* 2002, 18, 11, 791–796.
13. Curlin, M.E.; Zioni, R.; Hawes, S.E.; Liu, Y.; Deng, W.; Gottlieb, G.S.; Zhu, T.; Mullins, J.I. HIV-1 envelope subregion length variation during disease progression. PLoS Pathogens 2010, 6, e1001228.

14. Cormier, E.G.; Dragic, T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 2002, 76, 8953–8957.

15. Sander, O.; Sing, T.; Sommer, I.; Low, A.J.; Cheung, P.K.; Harrigan, P.R.; Lengauer, T.; Domingues, F.S. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Computational Biology 2007, 3, e58.

16. Gaschen, B.; Taylor, J.; Yusim, K.; Foley, B.; Gao, F.; Lang, D.; Novitsky, V.; Haynes, B.; Hahn, B.H.; Bhattacharya, T. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296, 2354–2360.

17. Gnanakaran, S.; Lang, D.; Daniels, M.; Bhattacharya, T.; Derdeyn, C.A.; Korber, B. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: Diversity and correlations in C3-V4 regions of gp120. J. Virol. 2007, 81, 4886–4891.

18. Rong, R.; Gnanakaran, S.; Decker, J.M.; Bibollet-Ruche, F.; Taylor, J.; Sfakianos, J.N.; Mokili, J.L.; Muldoon, M.; Mulenga, J.; Allen, S. Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 2007, 81, 5658–5668.

19. Patel, M.B.; Hoffman, N.G.; Swanstrom, R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 2008, 82, 903–916.

20. Holguín, A.; de Arellano, E.R.; Soriano, V. Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res. Hum. Retrovir. 2007, 23, 1067–1074.

21. Holguín, A.; Faudon, J.L.; Labernardière, J.L.; Soriano, V. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. J. Clin. Virol. 2007, 38, 176–180.

22. Sanders, R.W.; Korber, B.; Lu, M.; Berkhout, B.; Moore, J.P. Mutational analyses and natural variability of the gp41 ectodomain. HIV Sequence Compendium 2002, 2002, 43–68.

23. Razzolini, F.; Vicenti, I.; Saladini, F.; Micheli, V.; Romano, L.; Cargnel, A.; Zazzi, M. Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res. Hum. Retrovir. 2007, 23, 558–563.

24. Kuhmann, S.E.; Pugach, P.; Kunstman, K.J.; Taylor, J.; Stanfield, R.L.; Snyder, A.; Strizki, J.M.; Riley, J.; Baroudy, B.M.; Wilson, I.A. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78, 2790–2807.

25. Ogert, R.A.; Wojcik, L.; Buontempo, C.; Ba, L.; Buontempo, P.; Ralston, R.; Strizki, J.; Howe, J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373, 387–399.
26. Putcharoen, O.; Lee, S.H.; Henrich, T.J.; Hu, Z.; Vanichanan, J.; Coakley, E.; Greaves, W.; Gulick, R.M.; Kuritzkes, D.R.; Tsibris, A. HIV-1 Clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. *Science Signaling* 2012, 6, 1119.

27. Anastassopoulou, C.G.; Ketas, T.J.; Sanders, R.W.; Klasse, P.J.; Moore, J.P. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. *Virology* 2012, 482, 86–97.

28. Araújo, L.A.L.; Junqueira, D.M.; de Medeiros, R.M.; Matte, M.C.C.; Almeida, S.E.M. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC. *J. Clin. Virol* 2012, 54, 6–10.

29. Gonzalez, S.; Gondwe, C.; Tully, D.C.; Minhas, V.; Shea, D.; Kankasa, C.; M'soka, T.; Wood, C. Short communication: Antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia. *AIDS Res. Hum. Retrovir.* 2010, 26, 795–803.

30. Geretti, A.M.; Easterbrook, P. Antiretroviral resistance in clinical practice. *Int. J. STD AIDS*, 2006, 12, 145–153.

31. Ray, N.; Blackburn, L.A.; Doms, R.W. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. *J. Virol.* 2009, 83, 2989–2995.

32. Xu, L.; Pozniak, A.; Wildfire, A.; Stanfield-Oakley, S.A.; Mosier, S.M.; Ratcliffe, D.; Workman, J.; Joall, A.; Myers, R.; Smit, E. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. *Antimicrob. Agents Chemother.* 2005, 49, 1113–1119.

33. Baatz, F.; Nijhuis, M.; Lemaire, M.; Riedijk, M.; Wensing, A.M.J.; Servais, J.Y.; van Ham, P.M.; Hoepelman, A.I.M.; Koopmans, P.P.; Sprenger, H.G. Impact of the HIV-1 env genetic context outside HR1–HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates. *PloS One* 2011, 6, e21535.

34. Labrosse, B.; Morand-Joubert, L.; Goubard, A.; Rochas, S.; Labernardière, J.L.; Pacanowski, J.; Meynard, J.L.; Hance, A.J.; Clavel, F.; Mammano, F. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. *J. Virol.* 2006, 80, 8807–8819.

35. Reeves, J.D.; Gallo, S.A.; Ahmad, N.; Miamidian, J.L.; Harvey, P.E.; Sharron, M.; Pöhlmann, S.; Sfakianos, J.N.; Derdeyn, C.A.; Blumenthal, R. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. *Proc. Natl. Acad. Sci. U. S. A.* 2002, 99, 16249–16254.

36. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O'Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. *J. Virol.* 2000, 74, 8358–8367.
37. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Zhang, Z.; O'Brien, W.A.; Ratner, L.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. *J. Virol.* **2001**, *75*, 8605–8614.

38. Heil, M.L.; Decker, J.M.; Sfakianos, J.N.; Shaw, G.M.; Hunter, E.; Derdeyn, C.A. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. *J. Virol.* **2004**, *78*, 7582–7589.

39. Cilliers, T.; Patience, T.; Pillay, C.; Papathanasopoulos, M.; Morris, L. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. *AIDS Res. Hum. Retrovir.* **2004**, *20*, 477–482.

40. Yu, X.; Yuan, L.; Huang, Y.; Xu, W.; Fang, Z.; Liu, S.; Shao, Y.; Jiang, S.; Ma, L. Susceptibility of HIV-1 subtypes B’, CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. *PloS One* **2011**, *6*, e17605.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).